Compare PPG Industries, Inc. (PPG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PPG Industries, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? PPG Industries, Inc. trades at $105.43 (market cap $23.36B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.31B). The key difference: PPG Industries, Inc. is far larger — about 10.1× Recursion Pharmaceuticals Inc's market cap, and PPG Industries, Inc. pays a 2.82% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold PPG Industries, Inc. for 68 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| PPG | RXRX | |
|---|---|---|
Market Cap | $23.36B | $2.31B |
Volume | 1,972,399 | 40,478,768 |
Sector | Basic Materials | Health |
52-Week High | $131.56 | $6.79 |
52-Week Low | $94.34 | $2.84 |
Typical Hold Time | 68 Days | 22 Days |
Enterprise Value | $29.22B | $1.83B |
Dividend Yield | 2.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPG trades at $105.45, down 1.02% on the day, with a bearish technical signal from moving averages. The stock shows mixed earnings performance, missing Q4 2025 and Q2 2026 estimates but beating in Q1 2026. Fundamentals are solid with a P/E of 15.08, net income margin of 9.57%, and strong cash flow generation of $1.94B from operations in 2025. Recent news highlights margin pressures in the Automotive Refinish segment and upcoming Q3 2026 earnings on October 27.
The outlook is cautiously optimistic given analyst consensus favoring Buy with a $130 price target, implying 23% upside. Key opportunities include earnings growth and dividend stability, while risks involve segment-specific weakness and macroeconomic headwinds affecting demand. The stock's current valuation near support levels may attract value investors awaiting clearer earnings momentum.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
